On Friday, Flextronics International Ltd. (NASDAQ:FLEX)’s shares declined -2.09% to $10.29.
Flextronics (FLEX), a leading sketch-to-scale solutions company that designs and builds intelligent products for a connected world, declared recently that it has officially changed its name to Flex, with a promise to assist the world Live smarter™.
With its global scale and extensive physical infrastructure, Flex provides innovation, design, engineering, manufacturing and supply chain services to almost every industry, ranging from healthcare and automotive to industrial, energy, communications, enterprise computing and consumer electronics. This deep experience in multiple industries provides the Company with great intelligence and insight, improving visibility and velocity in a dynamic world.
Flextronics International Ltd. provides design, manufacturing, and supply chain services and solutions to original equipment manufacturers worldwide. The company offers innovation services, such as innovations labs for supporting customer design and product development services from early concept stages; collective innovation platform, an ecosystem of technology solutions; Lab IX startup accelerator program; centers of excellence solutions in critical areas; interconnect technology center for printed circuits; and CloudLabs that enables customers to accelerate a spectrum of cloud, converged infrastructure, and datacenter strategies.
Discovery Communications Inc. (NASDAQ:DISCA)’s shares dropped -1.44% to $26.73.
Discovery Communications, Inc. (DISCA) stated financial results for the second quarter ended June 30, 2015.
Second Quarter Results
Second quarter revenues of $1,654 million raised $44 million, or 3%, over the second quarter a year ago, led by 5% growth at U.S. Netoperates and 1% growth at International Netoperates. Adjusted Operating Income Before Depreciation and Amortization(1) (“OIBDA”) reduced 2% to $680 million, as 7% growth at U.S. Netoperates was more than offset by an 11% decline at International Netoperates and a small operating loss at Education and Other. Total Company revenues grew 11% and Adjusted OIBDA grew 6% not taking into account currency effects, as changes in foreign currency exchange rates reduced both second quarter revenue and Adjusted OIBDA growth by 8%. Not taking into account currency effects, the impact of Eurosport(2) and the consolidation of Discovery Family, total Company revenues raised 4% and Adjusted OIBDA raised 3%.
Discovery Communications, Inc. operates as a media company. The company operates through U.S. Netoperates; International Netoperates; and Education and Other segments. The company owns and operates television netoperates under the brands, such as Discovery, TLC, Animal Planet, Investigation Discovery, Science, Velocity, Discovery Family, American Heroes, Destination America, Discovery Life, Oprah Winfrey network, Eurosport, DMAX, and Discovery Kids. Its content spans genres, counting survival, exploration, sports, lifestyle, general entertainment, heroes, adventure, crime and investigation, health, and kids.
At the end of Friday’s trade, ZIOPHARM Oncology Inc. (NASDAQ:ZIOP)‘s shares surged 3.44% to $9.02.
ZIOPHARM Oncology, Inc. (ZIOP) declared financial results for the second quarter ended June 30, 2015, and offered an update on the company’s recent activities.
Recent Highlights
Ad-RTS-hIL-12
Ad-RTS-hIL-12 is a gene therapy candidate for the controlled expression of IL-12, a critical protein for stimulating an anti-cancer T cell immune response, using the RheoSwitch Therapeutic System(R) (RTS(R)) gene switch. In April 2015, ZIOPHARM declared the initiation of a Phase 1b/2 study of Ad-RTS-hIL-12 and veledimex following standard chemotherapy for the treatment of patients with locally advanced or metastatic breast cancer. In May 2015, the Company declared the initiation of a multi-center Phase 1 study of Ad-RTS-hIL-12 and veledimex in patients with recurrent or progressive glioblastoma multiforme, a form of brain cancer.
Both gene therapy trials, which are being conducted at leading centers across the U.S., are presently open and accruing patients. The Company anticipates that early results from each study will be presented at scientific meetings preceding to year end.
ZIOPHARM Oncology, Inc., a biotechnology company, employs gene expression, control, and cell technologies to deliver cell-based therapies for the treatment of cancer. Its synthetic immuno-oncology programs, in partnership with Intrexon Corporation and the MD Anderson Cancer Center, comprise chimeric antigen receptor T cell (CAR-T) and other adoptive cell based approaches that use both non-viral and viral gene transfer methods for broad scalability.
Baxalta Inc (NYSE:BXLT), ended its Friday’s trading session with -0.17% loss, and closed at $36.08.
Baxalta Incorporated (BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, recently declared that the company has accomplished the acquisition of the ONCASPAR (pegaspargase) portfolio from Sigma-Tau Finanziaria S.p.A. The acquisition comprises ONCASPAR, an important biologic treatment for patients with acute lymphoblastic leukemia (ALL), the novel investigational biologic calaspargase pegol, and established global clinical and commercial resources. Baxalta formerly declared plans to acquire the portfolio for about $900 million.
ONCASPAR is a biologic cancer therapy used as a component of multi-agent chemotherapeutic regimens to treat acute lymphoblastic leukemia (ALL), a rapidly progressing cancer of the white blood cells responsible for more than 80 percent of childhood leukemia cases. Standard of care regimens are highly effective in treating more than 80 percent of pediatric ALL patients in the United States.1
Baxalta Incorporated, a biopharmaceutical company, develops, manufactures, and markets a portfolio of products primarily for the treatment of hematology and immunology worldwide. It also offers other therapies for the treatments of bleeding disorders, and chronic and acute medical conditions, counting hemophilia A, hemophilia B, attained hemophilia, inhibitor treatments, primary immunodeficiency (PID), and alpha-1 antitrypsin deficiency.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
